- Home
- CCTG vs NLSP Comparison
CCTG vs NLSP Comparison
Compare CCTG & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCTG
- NLSP
- Stock Information
- Founded
- CCTG 1993
- NLSP 2015
- Country
- CCTG Hong Kong
- NLSP Switzerland
- Employees
- CCTG N/A
- NLSP N/A
- Industry
- CCTG
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- CCTG
- NLSP Health Care
- Exchange
- CCTG Nasdaq
- NLSP Nasdaq
- Market Cap
- CCTG 14.9M
- NLSP 12.4M
- IPO Year
- CCTG 2024
- NLSP 2021
- Fundamental
- Price
- CCTG $1.10
- NLSP $2.86
- Analyst Decision
- CCTG
- NLSP
- Analyst Count
- CCTG 0
- NLSP 0
- Target Price
- CCTG N/A
- NLSP N/A
- AVG Volume (30 Days)
- CCTG 5.9K
- NLSP 365.2K
- Earning Date
- CCTG 08-23-2025
- NLSP 07-07-2025
- Dividend Yield
- CCTG N/A
- NLSP N/A
- EPS Growth
- CCTG N/A
- NLSP N/A
- EPS
- CCTG N/A
- NLSP N/A
- Revenue
- CCTG $16,463,490.00
- NLSP N/A
- Revenue This Year
- CCTG N/A
- NLSP N/A
- Revenue Next Year
- CCTG N/A
- NLSP N/A
- P/E Ratio
- CCTG N/A
- NLSP N/A
- Revenue Growth
- CCTG 3.27
- NLSP N/A
- 52 Week Low
- CCTG $0.99
- NLSP $1.30
- 52 Week High
- CCTG $3.17
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- CCTG 45.98
- NLSP 67.56
- Support Level
- CCTG $1.05
- NLSP $2.19
- Resistance Level
- CCTG $1.12
- NLSP $2.54
- Average True Range (ATR)
- CCTG 0.04
- NLSP 0.19
- MACD
- CCTG 0.01
- NLSP 0.02
- Stochastic Oscillator
- CCTG 70.00
- NLSP 82.76
About CCTG CCSC Technology International Holdings Limited
CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas and Asia.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.